相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The clinical meaning of levodopa equivalent daily dose in Parkinson's disease
Charlotte Julien et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2021)
Treatment Options for Motor and Non-Motor Symptoms of Parkinson's Disease
Frank C. Church
BIOMOLECULES (2021)
An updated calculator for determining levodopa-equivalent dose
D. Nyholm et al.
NEUROLOGICAL RESEARCH AND PRACTICE (2021)
Predicting the longitudinal changes of levodopa dose requirements in Parkinson's disease using item response theory assessment of real-world Unified Parkinson's Disease Rating Scale
Dongwoo Chae et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2021)
A Real-Life Search for the Optimal Set of Conversion Factors to Levodopa-Equivalent-Dose in Parkinson's Disease Patients on Polytherapy
Muneer Abu Snineh et al.
JOURNAL OF PARKINSONS DISEASE (2020)
Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study
Nobutaka Hattori et al.
PARKINSONISM & RELATED DISORDERS (2020)
Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide
Sebastian Schade et al.
MOVEMENT DISORDERS CLINICAL PRACTICE (2020)
The Parkinson Pandemic-A Call to Action
E. Ray Dorsey et al.
JAMA NEUROLOGY (2018)
Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study
Emanuele Cereda et al.
JOURNAL OF NEUROLOGY (2017)
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations A Randomized Clinical Trial
Anthony H. V. Schapira et al.
JAMA NEUROLOGY (2017)
MDS clinical diagnostic criteria for Parkinson's disease
Ronald B. Postuma et al.
MOVEMENT DISORDERS (2015)
The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa
Roberto Cilia et al.
BRAIN (2014)
Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
Rupam Borgohain et al.
MOVEMENT DISORDERS (2014)
Two-Year, Randomized, Controlled Study of Safinamide as Add-on to Levodopa in Mid to Late Parkinson's Disease
Rupam Borgohain et al.
MOVEMENT DISORDERS (2014)
Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease
A. H. V. Schapira et al.
EUROPEAN JOURNAL OF NEUROLOGY (2013)
Neurostimulation for Parkinson's Disease with Early Motor Complications
W. M. M. Schuepbach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A Randomized, Double-Blind, Placebo-Controlled Trial of Safinamide as Add-on Therapy in Early Parkinson's Disease Patients
Fabrizio Stocchi et al.
MOVEMENT DISORDERS (2012)
Meta-Analysis of the Comparative Efficacy and Safety of Adjuvant Treatment to Levodopa in Later Parkinson's Disease
Rebecca Stowe et al.
MOVEMENT DISORDERS (2011)
Milestones in Parkinson's Disease Therapeutics
Olivier Rascol et al.
MOVEMENT DISORDERS (2011)
Systematic Review of Levodopa Dose Equivalency Reporting in Parkinson's Disease
Claire L. Tomlinson et al.
MOVEMENT DISORDERS (2010)
A clinico-pathological study of subtypes in Parkinson's disease
M. Selikhova et al.
BRAIN (2009)
Irreversible motor impairment in young addicts - ephedrone, manganism or both?
K. Sikk et al.
ACTA NEUROLOGICA SCANDINAVICA (2007)
Safinamide - From molecular targets to a new anti-Parkinson drug
C. Caccia et al.
NEUROLOGY (2006)
Motor impairment in PD - Relationship to incident dementia and age
G Levy et al.
NEUROLOGY (2000)
分享论文
